Tag: Cancer: Prostate
Prostate Cancer Trial Participants Overwhelmingly White
Since 1990, proportion of white participants in prostate cancer clinical trials has remained >80 percent
ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer
And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer
Local-Stage Prostate Cancer Incidence Rates Continue to Drop
Rates of regional- and distant-stage prostate cancer increasing in the U.S. among men aged ≥50 years
Risk for SARS-CoV-2 Lower for Prostate Cancer Patients on ADT
Risk reduced fourfold with androgen-deprivation therapy versus other treatment for prostate cancer
Genomically Targeted Treatment Slows Advanced Prostate Cancer
Men receiving olaparib versus standard treatment experience delayed disease progression
Racial Disparity in Prostate Cancer Survival Tied to Region
Mortality risk for low-risk prostate cancer more than fivefold higher for black versus white men in Atlanta
Radiotherapy for Prostate Cancer Adjusted During COVID-19
Telemedicine consults recommended; treatment can be avoided, delayed in low, intermediate-risk disease
10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT
Combined Biopsy Method Better for Prostate Cancer Diagnosis
Cancer diagnosed in 9.9 percent more, upgrading seen in 21.8 percent with MRI-targeted + systematic biopsy
Surgical Approach Not Tied to Decision Regret After Prostatectomy
Functional and oncologic outcomes, autonomous decision-making, and follow-up time influence regret
